Pembrolizumab and stereotactic radiotherapy combined in subjects with advanced HCC: A phase II study (PEMRAD).
| Publicado en: | Journal of Clinical Oncology Vol. 43; pp. 602 - 734 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2025 Supplement 4
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=182479301&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 182479301 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0732183X 20D jtl: Journal of Clinical Oncology issn: 0732183X maglogo: N pubinfo: dt: 2025 Supplement 4 vid: 43 pid: 26892 pub: American Society of Clinical Oncology place: Alexandria, Virginia artinfo: ui: 182479301 10.1200/JCO.2025.43.4_suppl.602 182479301 ppf: 602 ppct: 132 formats: tig: atl: Pembrolizumab and stereotactic radiotherapy combined in subjects with advanced HCC: A phase II study (PEMRAD). aug: au: O'Kane, Grainne M. Mesci, Aruz M Chen, Eric Xueyu Bocaya, Cynthia M Jang, Raymond Woo-Jun Wang, Ben X Prince, Rebecca M. Boukhaled, Giselle M Barry, Aisling S Doherty, Mark Wong, David K Wang, Lisa Dodd, Anna Dawson, Laura A. Knox, Jennifer J. affil: St Vincent's University Hospital, Dublin, Ireland sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|